Cancer research unlocks 30-year genetic puzzle

June 12, 2012

(Medical Xpress) -- Scientists at the University of Sussex have solved a 30-year genetic puzzle that could help enhance treatment for certain types of “inherited” cancers.

The findings relate to an enzyme that plays an important role in the repair of DNA – the genetic blueprint for all life which in mutated form leads to the uncontrolled reproduction of cells and the development of cancers.

The enzyme – PARP1 – was first identified as a DNA damage sensor by Professor Sydney Shall in research undertaken at Sussex in the 1980s. Its discovery led to the development of drugs that blocked the DNA repair mechanism in breast, prostate and ovarian cancers found in people who have a family history of those diseases.

But for the past three decades scientists have not known exactly how the enzyme recognised and repaired DNA damage.

The Cancer Research UK-funded study by the Genome Damage and Stability Centre at Sussex and  the Adolf Butenandt Institute, University of Munich has now shown, using structural biology, biochemistry and cell imaging techniques, that two PARP1 cooperate with each other to detect the damage and then signal to other molecules to bind together at the damage site.

The team’s findings are published online (10 June 2012)  in Nature Structural and Molecular Biology.

The team, led by Professor Laurence Pearl and Dr Antony Oliver have now discovered that molecules within the enzyme, known as PARP1, cooperate to identify DNA damage and then signal to other molecules to bind together and repair the damage on site.

Professor Laurence Pearl, who is head of Life Sciences at the University of Sussex and who led the research with Dr Antony Oliver, says: “When the PARP1 molecules bind together at the site of DNA damage, they cooperate to generate a large molecular ‘flag’ called polyADP-ribose, that signals to other molecules in the cell to come and repair the broken DNA.

“Drugs that stop PARP1 from signaling kill a range of breast, ovarian and prostate cancers in people whose tumours have defects in other DNA systems, and who often come from families with a strong genetic predisposition to those diseases. Now we have a clearer idea of how PARP1 actually recognises damaged DNA and fires off its DNA damage signal, we can target this system with far greater precision.”

The detailed knowledge of how PARP1 signals DNA damage will greatly assist the development of the next generation of drugs that exploit the changes that cause cancers, to kill them, while sparing normal tissues and causing far fewer side effects.

Explore further: Bacteria shed light on new drug targets for inherited cancers

More information:

Related Stories

Bacteria shed light on new drug targets for inherited cancers

September 6, 2011

Cancer Research UK scientists have succeeded in purifying a protein found in bacteria that could reveal new drug targets for inherited breast and ovarian cancers - and other cancers linked to DNA repair faults. The study ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.